CTTI Selects Three New Patient/Caregiver Representatives for Steering Committee
CTTI is delighted to welcome three new patient/caregiver representatives, Jamil Rivers, Phil Green, and Nuru Noor, to our Steering Committee.
The new patient/caregiver representatives will play a key role alongside the existing CTTI members in CTTI activities to advance CTTI’s vision to Transform Trials 2030. Their voices and contributions will add valuable insight and create transformative practices that advance the future of clinical trials.
Each new representative brings a remarkable background and set of experiences they will use to communicate the current needs of patients and caregivers. Please find additional information about them below.
Welcome Jamil, Phil, and Nuru – we are excited to have you on board!
Jamil Rivers
Jamil Rivers was diagnosed at age 39 with metastatic breast cancer. As someone who holds a Bachelor of Science degree from Rutgers University, two master’s degrees from the University of Southampton and Acadia University, as well as many specialized certifications, Ms. Rivers understands the power of knowledge. In preparation for her battle to survive, she conducted extensive, meticulous research. This led her to a combination of treatments including chemotherapy, improved nutrition, and integrative therapies which have helped her improve and lead an active life that includes hormone therapy.
In 2019, Ms. Rivers used her background in finance, education, and non-profit leadership to launch The Chrysalis Initiative which helps to address treatment disparities and inequities and improve breast cancer outcomes by providing education and navigational support for patients and providers. She also harnesses her knowledge and expertise to benefit several advocacy organizations where she serves on the board and holds other positions.
Ms. Rivers is currently the CFO at Educationworks, Inc. She and her husband, Rick, have three children and reside in Pennsylvania.
Phil Green
When Phil Green was diagnosed with ALS in August of 2018, he immediately dedicated himself to making a difference in the fight against this horrific disease. As a former University of Washington football player on the 1991 national championship team, he knows the value of perseverance. He committed the next 25 years to building a successful career leading companies and teams to develop innovative technology solutions that helped brands such as Sony, Hewlett Packard, and Home Depot.
Today, Mr. Green applies this same dedication, knowledge, and work ethic to help multiple ALS organizations increase awareness of the condition, promote legislation, and raise funds. This devotion extends to a wide array of organizations that span the advocacy, biotech, and research sectors. These include Augie’s Quest, Team Gleason, I AM ALS, the International Alliance of ALS/MND Associations and others where he serves in a variety of leadership and advisory roles.
Mr. Green retired as the VP of Digital Innovation at Beeline Group and lives in California with his wife, Jennifer, and their four children.
Nuru Noor
Nuru Noor’s decision to go into medicine was shaped at an early age by witnessing the impact that medical conditions like diabetes and cancer had on his close family members. These profound, personal experiences left him with a deep appreciation for the challenges faced by both patients and caregivers. It also fueled a commitment for working with people to help them improve their quality of life and minimize the impact of medical conditions on their day-to-day activities. Now, as a fellow at the Cambridge University Hospital NHS Trust in Cambridge, U.K., Mr. Noor combines his insight as a caregiver with his education and proficiency in medicine. He has also worked at a number of volunteer organizations, including a stroke rehabilitation group where he helped people set their targets and meet physical activity goals.
Mr. Noor believes clinical trials should be inclusive and a part of standard clinical care for all patients. His view is that research questions and interventions should address areas of unmet need and that trials should aim to answer questions most important to patients and caregivers. Mr. Noor’s goal is to make a significant contribution that supports his passion for more efficient clinical trial designs. This, in turn, will help to ensure patients receive better treatments at a much faster rate.